Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2012

01-12-2012 | Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Interventions to Address Chronic Disease and HIV: Strategies to Promote Smoking Cessation Among HIV-infected Individuals

Authors: Raymond Niaura, Geetanjali Chander, Heidi Hutton, Cassandra Stanton

Published in: Current HIV/AIDS Reports | Issue 4/2012

Login to get access

Abstract

Tobacco use, especially cigarette smoking, is higher than average in persons living with HIV/AIDS (PLWHA). The Public Health Service Clinical Practice Guideline for Treating Tobacco Use and Dependence states that, during every medical encounter, all smokers should be offered smoking cessation counseling, along with approved medications. The Guideline also recognizes PLWHA as a priority population, given the scarcity of research on effective cessation treatments in this group. The scant evidence suggests that conventional treatments, though worthwhile, are not as successful as might be hoped for. The reasons for this are not entirely clear, but may have to do with the complex array of medical and psychosocial factors that complicate their lives. Clinicians should consider re-treatment strategies for those patients who encounter difficulty when quitting smoking with conventional approaches, switching or augmenting treatments as needed to minimize adverse experiences, and to maximize tolerability, adherence, and cessation outcomes.
Literature
1.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238.PubMedCrossRef
2.
Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7:511–22.PubMedCrossRef
3.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824–35.PubMedCrossRef
4.
Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31:808–12.PubMedCrossRef
5.
Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine cohort. AIDS Patient Care STDS. 2007;21:458–68.PubMedCrossRef
6.
Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Betancourt RM, Stein M, Tashima K, et al. HIV-positive smokers considering quitting: differences by race/ethnicity. Am J Health Behav. 2008;32:3.PubMedCrossRef
7.
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8:313–9.PubMedCrossRef
8.
Gritz ER, Vidrine DJ, Lazev AB, Amick BCI, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6:71–7.PubMedCrossRef
9.
• Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9(3):223–30. A comprehensive review of the health consequences of smoking in HIV-infected patients.
10.
Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43(1):90–8.PubMedCrossRef
11.
Patel N, Talwar A, Reichert VC, Brady T, Jain M, Kaplan MH. Tobacco and HIV. Clin Occup Environ Med. 2006;5:193.PubMed
12.
13.
Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, Veterans Aging Cohort 5 Project Team. Increased COPD among HIV-positive compared with HIV-negative veterans. Chest. 2006;130:1326–33.PubMedCrossRef
14.
Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142–5.PubMedCrossRef
15.
Crothers K, Tindle HA. Prevention of bacterial pneumonia in HIV infection: focus on smoking cessation. Expert Rev Anti Infect Ther. 2011;9:759–62.PubMedCrossRef
16.
Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53:102–6.PubMedCrossRef
17.
Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896–903.
18.
Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12(7):412–21.
19.
Piper ME, Kenford S, Fiore MC, Baker TB. Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt. Ann Behav Med. 2011;43(2):262–70.
20.
Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS. AIDS Patient Care STDS. 2007;21:659–66.PubMedCrossRef
21.
Flicker L. Modifiable lifestyle risk factors for Alzheimer’s disease. J Alzheimers Dis. 2010;20:803–11.PubMed
22.
Lasser K, Boyd J, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606.PubMedCrossRef
23.
Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health Report. Nicotine Tob Res. 2008;10:1691–715.PubMedCrossRef
24.
McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. 2010;100:2464–72.PubMedCrossRef
25.
Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts H, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the Women's Interagency HIV Study. Am J Public Health. 2006;96:1060–5.PubMedCrossRef
26.
Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731–6.PubMedCrossRef
27.
Marks King R, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, et al. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012;26(8):479–85.
28.
Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev. 2009;21(3 Suppl):106–21.PubMedCrossRef
29.
Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21 Suppl 3:54–64.PubMedCrossRef
30.
31.
Cox LS, Okuyemi K, Choi WS, Ahluwalia JS. A review of tobacco use treatments in U.S. ethnic minority populations. Am J Health Promot. 2011;25(5 Suppl):S11–30.PubMed
32.
Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service Report. Am J Prev Med. 2008;35:158–76.
33.
Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher HC, et al. A smoking cessation program in HIV-infected individuals: a pilot study. Antivir Ther. 2006;11:787–95.PubMed
34.
Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545–54.PubMedCrossRef
35.
Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2011;14:106–10.PubMedCrossRef
36.
Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr. 2012. doi:10.​1097/​QAI.​0b013e3182645679​.
37.
Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, et al. Motivation and patch treatment for HIV + smokers: a randomized controlled trial. Addiction. 2009;104:1891–900.PubMedCrossRef
38.
Stanton CA, Lloyd-Richardson EE, Papandonatos GD, de Dios MA, Niaura R. Mediators of the relationship between nicotine replacement therapy and smoking abstinence among people living with HIV/AIDS. AIDS Educ Prev. 2009;21(3 Suppl):65–80.PubMedCrossRef
39.
Pedrol-Clotet E, Deig-Comerma E, Ribell-Bachs M, Vidal-Castell I, García-Rodríguez P. Soler A [Bupropion use for smoking cessation in hiv-infected patients receiving antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2006;24:509–11.PubMedCrossRef
40.
Tornero C, Mafé C. Varenicline and antiretroviral therapy in patients with HIV. J Acquir Immune Defic Syndr. 2009;52:656.PubMed
41.
Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, et al. Safety and tolerability of varenicline tartrate (champix(®)/chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS. 2011;26(1):12–19.
42.
Shuter J, Salmo LN, Shuter AD, Nivasch EC, Fazzari M, Moadel AB. Provider beliefs and practices relating to tobacco use in patients living with HIV/AIDS: a national survey. AIDS Behav. 2011;16(2):288–94.
43.
Kirshenbaum AP, Olsen DM, Bickel WK. A quantitative review of the ubiquitous relapse curve. J Subst Abuse Treat. 2009;36:8–17.PubMedCrossRef
44.
Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29–38.PubMedCrossRef
45.
Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. Addict Behav. 2008;33:1516–20.PubMedCrossRef
46.
Huber M, Ledergerber B, Jaccard R, Elzi L, Furrer H, Hirschel B, et al. Smoking prevalence, cessation rates and relapse rates in the Swiss HIV cohort study (SHCS). J Int AIDS Soc. 2010;13:1–2.CrossRef
47.
Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Status and date: new search for studies and content updated (conclusions changed), Published in 2009. Cochrane Database Syst Rev. 2009;21(1):CD003999.
48.
• Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362–80. A comprehensive review of behavioral and pharmacologic smoking relapse prevention treatments, along with meta-analyses. PubMedCrossRef
49.
Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol. 1990;58:85–92.PubMedCrossRef
50.
Fortmann SP, Killen JD. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. J Consult Clin Psychol. 1995;63:460–8.PubMedCrossRef
51.
Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82:186–95.PubMed
52.
Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102:1292–302.PubMedCrossRef
53.
Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135:423–33.PubMed
54.
Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003;21:914.PubMedCrossRef
55.
Killen JD, Fortmann SP, Murphy GM, Hayward C, Arredondo C, Cromp D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol. 2006;74:286–94.PubMedCrossRef
56.
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.PubMedCrossRef
57.
Joseph AM, Rice K, An LC, Mohiuddin A, Lando H. Recent quitters' interest in recycling and harm reduction. Nicotine Tob Res. 2004;6:1075.PubMedCrossRef
58.
Fu SS, Partin MR, Snyder A, An LC, Nelson DB, Clothier B, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care. 2006;12:235–43.PubMed
59.
Cupertino AP, Wick JA, Richter KP, Mussulman L, Nazir N, Ellerbeck EF. The impact of repeated cycles of pharmacotherapy on smoking cessation: a longitudinal cohort study. Arch Intern Med. 2009;169:1928–30.PubMedCrossRef
60.
Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2008;34:426–32.PubMedCrossRef
61.
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Executive Summary. Rockville MD: US Department of Health and Human Services. Public Health Service. May 2008.
62.
Niaura R, Abrams DB. Smoking cessation: progress, priorities, and prospectus. J Consult Clin Psychol. 2002;70:494.PubMedCrossRef
63.
Abrams DB, Orleans CT, Niaura RS, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: a combined stepped-care and matching model. Ann Behav Med. 1996;18:290–304.PubMedCrossRef
64.
Sobell MB, Sobell LC. Stepped care as a heuristic approach to the treatment of alcohol problems. J Consult Clin Psychol. 2000;68:573.PubMedCrossRef
65.
Breslin FC, Sobell MB, Sobell LC, Cunningham JA, Sdao-Jarvie K, Borsoi D. Problem drinkers: evaluation of a stepped-care approach. J Subst Abuse. 1998;10:217–32.PubMedCrossRef
66.
Murphy SA, Lynch KG, Oslin D, McKay JR, TenHave T. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007;88 Suppl 2:S24–30.PubMedCrossRef
67.
Hughes JR, Grass JA, Pillitteri JL. Treatment resistant smokers: a pilot study of nicotine nasal spray and inhaler. J Addict Dis. 2000;19:95–100.PubMedCrossRef
68.
Tønnesen P, Nørregaard J, Säwe U, Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction. 1993;88:533–9.PubMedCrossRef
69.
Tonnesen P, Mikkelsen K, Norregaard J, Jorgensen S. Recycling of hard-core smokers with nicotine nasal spray. Eur Respir J. 1996;9:1619.PubMedCrossRef
70.
Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ. 1995;311:363–6.PubMedCrossRef
71.
Smith SS, Jorenby DE, Fiore MC, Anderson JE, Mielke MM, Beach KE, et al. Strike while the iron is hot: can stepped-care treatments resurrect relapsing smokers? J Consult Clin Psychol. 2001;69:429.PubMedCrossRef
72.
Gonzalez DH, Nides M, Ferry LH, Segall N, Herrero LA, Krishen A, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther. 2001;69:438–44.CrossRef
73.
Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206.PubMed
74.
Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008;59:443–53.PubMedCrossRef
75.
Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med. 2008;148:554–6.PubMed
76.
Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med. 2011;171:1894–900.PubMedCrossRef
77.
Chakraborty B. Dynamic treatment regimes for managing chronic health conditions: a statistical perspective. Am J Public Health. 2011;101:40–5.PubMedCrossRef
78.
Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin Trials. 2004;1:9.PubMedCrossRef
79.
Chakraborty B, Murphy S, Strecher V. Inference for non-regular parameters in optimal dynamic treatment regimes. Stat Methods Med Res. 2010;19:317–43.PubMedCrossRef
80.
Murphy SA, Van Der Laan MJ, Robins JM. Marginal mean models for dynamic regimes. J Am Stat Assoc. 2001;96:1410–23.PubMedCrossRef
81.
Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24:1455–81.PubMedCrossRef
82.
• Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A "SMART" design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21–48. A good review of how to conceive of, construct, and test adaptive treatment strategies. PubMedCrossRef
83.
Pineau J, Bellemare MG, Rush AJ, Ghizaru A, Murphy SA. Constructing evidence-based treatment strategies using methods from computer science. Drug Alcohol Depend. 2007;88 Suppl 2:S52–60.PubMedCrossRef
84.
Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, et al. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of 4 regimens. J Natl Cancer Inst. 2007;99:1613–22.PubMedCrossRef
85.
Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent health interventions. Am J Prev Med. 2007;32(5 Suppl):S112–8.PubMedCrossRef
86.
Dawson R, Green AI, Drake RE, McGlashan TH, Schanzer B, Lavori PW. Developing and testing adaptive treatment strategies using substance-induced psychosis as an example. Psychopharmacol Bull. 2008;41:51–67.PubMed
87.
Buyze J, Van Rompaye B, Goetghebeur E. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients. Stat Med. 2010;29:1114–26.PubMed
88.
Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1–25.PubMedCrossRef
89.
Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011;2:CD006103.
90.
Hughes J, Stead L, Lancaster T, Rev CDS. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
91.
Carrozzi L, Pistelli F, Viegi G. Pharmacotherapy for smoking cessation. Ther Adv Respir Dis. 2008;2:301–17.PubMedCrossRef
92.
Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010;49:799–816.PubMedCrossRef
93.
Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11:234–9.PubMedCrossRef
Metadata
Title
Interventions to Address Chronic Disease and HIV: Strategies to Promote Smoking Cessation Among HIV-infected Individuals
Authors
Raymond Niaura
Geetanjali Chander
Heidi Hutton
Cassandra Stanton
Publication date
01-12-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-012-0138-4

Other articles of this Issue 4/2012

Current HIV/AIDS Reports 4/2012 Go to the issue

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Housing Status and the Health of People Living with HIV/AIDS

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Interventions to Improve Retention in HIV Primary Care: A Systematic Review of U.S. Studies

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Deadly Public Policy: What the Future Could Hold for the HIV Epidemic among Injection Drug Users in Vancouver

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Interventions to Improve Psychological Functioning and Health Outcomes of HIV-Infected Individuals with a History of Trauma or PTSD

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Interventions to Address Chronic Disease and HIV: Strategies to Promote Exercise and Nutrition Among HIV-Infected Individuals

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Motivational Interviewing Targeting Risk Reduction for People with HIV: A Systematic Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits